会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明公开
    • 결합조직 성장인자를 이용한 약학적 조성물
    • 使用连接组织生长因子的药物组合物
    • KR1020110120195A
    • 2011-11-03
    • KR1020100132775
    • 2010-12-22
    • 포항공과대학교 산학협력단
    • 류성호이미숙서판길김완욱
    • A61K38/18A61K38/16A61P9/10A61P9/00
    • A61K38/18
    • PURPOSE: A pharmaceutical composition related to angiogenesis using connective-tissue growth factors is provided to effectively induce FPRL1-specific ERK phosphorylation. CONSTITUTION: A composition for promoting angiogenesis contains a fragment of connective-tissue growth factor having 38 or more serial amino acids having an amino acid of sequence number 5 or a gene encoding the same as an active ingredient. The fragment of the connective-tissue growth factor is denoted by sequence number 5 or 6. A siRNA of FPRL1(formyl peptide receptor-like 1) has sequence numbers 3 and 4. A composition for promoting angiogenesis contains the siRNA as an active ingredient.
    • 目的:提供与使用结缔组织生长因子的血管生成相关的药物组合物,以有效诱导FPRL1特异性ERK磷酸化。 构成:用于促进血管发生的组合物含有具有38个或更多个具有序列号5的氨基酸的序列氨基酸的结缔组织生长因子的片段或与其编码活性成分的基因。 结缔组织生长因子的片段由序列号5或6表示.FPRL1(甲酰基肽受体样1)的siRNA具有序列号3和4.用于促进血管生成的组合物含有siRNA作为活性成分。
    • 48. 发明公开
    • 면역 조절 펩타이드
    • 免疫调节肽
    • KR1020070108836A
    • 2007-11-13
    • KR1020070106121
    • 2007-10-22
    • 주식회사 포스코포항공과대학교 산학협력단
    • 류성호서판길배외식송지영
    • C07K7/06A61K38/00
    • C07K7/06A61K38/00C07K5/081C07K5/1016C07K5/1019C12N2799/021
    • An immune-modulating peptide is provided to reduce or inhibit side effects of drug and drug candidate materials by activating formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1) expressed from phagocytic cells, thereby activating various molecules and inducing downstream signaling. An immune-modulating peptide comprises one selected from the amino acid sequences of SEQ ID NO:1 to SEQ ID NO:24, and has at least one properties selected from (a) induction of superoxide production in human monocyte or neutrophil, (b) binding with formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1), (c) induction of in vitro chemotactic migration of human monocyte or neutrophil, (d) induction of degranulation in formyl peptide receptor-like 1(FPRL1) expression cells, (e) increase of extracellular signal-controlled protein kinase phosphorylation through binding with formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1), and (f) increase protein kinase B(Akt) phosphorylation through binding with formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1).
    • 通过激活吞噬细胞表达的甲酰肽受体(FPR)和甲酰肽受体样1(FPRL1),从而激活各种分子并诱导下游信号传导,提供免疫调节肽以减少或抑制药物和药物候选物质的副作用 。 免疫调节肽包含选自SEQ ID NO:1至SEQ ID NO:24的氨基酸序列的一种,并且具有选自(a)在人单核细胞或嗜中性粒细胞中诱导超氧化物产生的至少一种性质,(b) 结合甲酰肽受体(FPR)和甲酰肽受体样1(FPRL1),(c)诱导人单核细胞或嗜中性粒细胞的体外趋化迁移,(d)诱导甲酰肽受体样1(FPRL1)中的脱颗粒 表达细胞,(e)通过与甲酰基肽受体(FPR)和甲酰肽受体样1(FPRL1)结合增加细胞外信号控制的蛋白激酶磷酸化,和(f)通过与...结合而增加蛋白激酶B(Akt)磷酸化 甲酰肽受体(FPR)和甲酰肽受体样1(FPRL1)。